Assoc. Prof. Dr. Elif Şenocak Taşçı
Medical Oncology
About Elif Şenocak Taşçı
Assoc. Prof. Elif Şenocak Taşçı is a medical oncologist affiliated with Acıbadem Health Group. She completed her medical oncology training at Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine in 2023 and has continued her clinical and academic work within the Acıbadem network since 2025. Known for a patient-centered approach, she combines evidence-based cancer care with clear communication and compassionate support for patients and families. Her interests include delivering personalized treatment plans, participating in multidisciplinary care, and staying current with advances in oncology to improve outcomes and quality of life for those she treats.
Subspecialties
- Metastatic melanoma
- Advanced gastric cancer
- Gastroesophageal junction cancer
- Esophageal adenocarcinoma
- Locally advanced rectal cancer
- Relapsed or refractory Hodgkin lymphoma
- Triple-negative breast cancer
- Immune checkpoint inhibitor therapy
- Nivolumab plus chemotherapy
- Total neoadjuvant therapy
- Neoadjuvant chemoradiation
- Adjuvant capecitabine therapy
- Perioperative FLOT chemotherapy
- BEGEV chemotherapy
Education
- 2023 Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine Medical Oncology
- 2017 Duzce University Faculty of Medicine Internal Medicine
- 2012 Yeditepe University Faculty of Medicine
Experience
- 2025 Acibadem Health Group
- 2023 – 2025 Kanuni Sultan Süleyman Training and Research Hospital / Medical Oncology Specialist
- 2019 – 2020 Haydarpasa Numune Training and Research Hospital / Internal Medicine Specialist
Selected Publications
- A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy. J Clin Oncol. 2025 ;43(16_suppl): 1203 3. Goktas Aydin S, Aydin A, Demirel BC, et al.
- Predicting osteoporosis in elderly cancer patients using the modified Glasgow prognostic index Cancer Control. 2025;32:10732748251337601. Ustuner M, Goktas Aydin S, Aydin A, et al
- Real world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: a Turkish oncology group retrospective study. Mol Clin Oncol. 2025;22(6):51. Ozgun A, Mustafayev FNA, Dogan I, et al
- Assessment of health literacy and HPV knowledge among university students: an observational study Medicine (Baltimore). 2024; 103(35). Senocak Tasci E, Bas D, Kayak S, et al.
- Real-world efficacy and safety of fırst-line nivolumab plus chemotherapy in patients with advanced gastric, gastroesophageal junction, and esophageal esophageal adenocarcinoma: a nationwide observational Turkish Oncology Group (TOG) study. Cancers (Basel). 2024; 16(12):2251. Kutlu Y, Shute DA, Yilmaz F, et al.
- Total neoadjuvant therapy versus neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional real-world study. Cancers (Basel). 2024; 16( 18):3213. Senocak Tasci E, Mutlu AU, Saylik O, et al
- BEGEV is an effective therapy for heavily pretreated and platinum-resistant relapsed/refractory Hodgkin’s lymphoma patients: a single-center real-life experience. Indian J Hematol Blood Transfus. 2024 Uzay A, Tasci ES, Gundogdu Y, et al.
- Efficacy of adjuvant capecitabine in residual triple-negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opin Pharmacother. 2024:1-8. Tasci ES, Kutlu Y, Ölmez ÖF, et al
- Turkish adaptation of QEQ-SH22 quality of sexual life assessment scale in cancer patients – validity and reliability study Sisli Etfal Hastan Tip Bul. 2024;58(4):468-476. Eriş SB, Celayir OM, Tasci ES, et al.
- Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group). Turkish J Med Sci. 2022;52(4): 1022-1032. Erol C, Sakin A, Basoglu T, et al.
Schedule your appointment with Assoc. Prof. Dr. Elif Şenocak Taşçı
Choose a date and time that suits you. Our international patient team will check availability and confirm your appointment — usually within 24 hours.
- 1Choose your date & timePick a preferred day and time slot for your visit.
- 2Share your detailsTell us how to reach you and anything we should know.
- 3We confirm with youOur team confirms the appointment by phone or email.
Request your appointment
This request goes directly to this doctor’s schedule.
Your information stays strictly confidential and is used only to arrange your care.